Overview
Product name | Recombinant Human HER1/ERBB1/EGFR Protein |
---|
Catalog No. | RP01029 |
---|
Description | Recombinant Human HER1/ERBB1/EGFR Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met1-Ser645) of human EGFR (Accession #NP_005219.2. ) fused with an Fc, 6×His tag at the C-terminus. |
---|
Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized recombinant human EGF at 0.5 μg/mL (100 μL/well) can bind Rrecombinant human EGFR with a linear range of 0.3-2.5 μg/mL.
|
---|
Purity | > 90% by SDS-PAGE. |
---|
Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
---|
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
---|
Species | Human |
---|
Calculated MW | 97.64 kDa |
---|
Background
The EGFR (epidermal growth factor receptor) subfamily of receptor tyrosine kinases comprises four members: EGFR (also known as HER-1, ErbB1, or ErbB), ErbB2 (Neu, HER-2), ErbB3 (HER-3), and ErbB4 (HER-4). EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc.The human EGFR cDNA encodes a 1210 amino acid (aa) precursor with a 24 aa signal peptide, a 621 aa extracellular domain (ECD), a 23 aa transmembrane segment, and a 542 aa cytoplasmic domain. EGFR signaling has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently, which is overexpressed in a wide variety of tumors and is the target of several anti-cancer drugs.
Product information
Synonym | EGFR; ERBB; ERBB1; HER1; NISBD2; PIG61; mENA; epidermal growth factor receptor; ERBB; ERBB1; HER1; NISBD2; PIG61; mENA |
---|
Expression Host | HEK293 cells |
---|
Tag | C-hFc&His |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.